Eyeworld Daily News

23 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, Los Angeles 2017 Best paper of session winners High-Resolution OCT Imaging of Bowman Layer in Asymmetric Keratoconus Roshan T, MD Diagnostic Usefulness of Anterior Chamber Paracentesis with Poly- merase Chain Reaction in Corneal Endotheliitis Seong Jae Kim, MD, PhD Multicenter Open-Label Study of the Performance of a New Gel Stent in Refractory Glaucoma in the United States Arsham Sheybani, MD Efficacy of a New Pupil-Expansion Device in Cataract Surgery: First 30 Cases Sergio Canabrava, MD Prospective, Randomized Study Comparing Visual Outcomes of an Accommodating IOL and 2 Multifo- cal IOLs: 5-Year Follow-up Robert Edward Ang, MD Optimizing the Inflammatory Re- sponse After Excimer Laser Abla- tion Using Molecular Inflammatory Markers Emilio Torres Netto, MD Neodymium:YAG Laser Vitreolysis: Retrospective Safety Study Inder Singh, MD Comparison of Femtosecond Laser-Assisted Descemetorhexis and Manual Descemetorhexis in Descemet Membrane Endothelial Keratoplasty Adi Einan-Lifshitz, MD Planned Descemetorhexis Without Endothelial Keratoplasty in Eyes with Fuchs' Corneal Endothelial Dystrophy Alain Saad, MD EW Ultrasound Energy in Different Nuclear Densities During Laser- Assisted Versus Conventional Cataract Surgery Ahmed Assaf, MD Small-Incision Lenticule Extraction for Hyperopia: Visual and Refrac- tive Outcomes, Optical Zone Cen- tration, Diameter, and Aberration Induction Dan Reinstein, MD Multicenter Defocus Curve Evalu- ation of a New Trifocal Presbyopia Correcting IOL—6-month Postop- erative Results Thomas Kohnen, MD Indication LOTEMAX ® GEL (loteprednol etabonate ophthalmic gel) 0.5% is indicated for the treatment of post-operative infl ammation and pain following ocular surgery. Important Safety Information about LOTEMAX ® GEL • LOTEMAX ® GEL is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored. • Use of corticosteroids may result in posterior subcapsular cataract formation. • Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation and occurrence of perforations in those with diseases causing corneal and scleral thinning. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, and where appropriate, fluorescein staining. • Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infection. In acute purulent conditions, steroids may mask infection or enhance existing infection. • Use of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and exacerbate the severity of many viral infections of the eye (including herpes simplex). • Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. • Patients should not wear contact lenses when using LOTEMAX ® GEL. • The most common ocular adverse drug reactions reported were anterior chamber inflammation (5%), eye pain (2%) and foreign body sensation (2%). Please see brief summary of Prescribing Information on adjacent page. ®/™ are trademarks of Bausch & Lomb Incorporated or its a liates. © 2015 Bausch & Lomb Incorporated. All rights reserved. Printed in USA. US/LGX/15/0041(1) Down, Boy. Help Tame Postoperative Ocular Inflammation and Pain With LOTEMAX ® GEL

• Cover